Member nations of the World Health Organization have renewed calls for constructive engagement on one of the most contentious issues in global health governance — the access to pathogens and the equitable sharing of benefits derived from their use. The push comes amid ongoing discussions to finalize international arrangements that would govern how countries share biological samples of disease-causing organisms and ensure that advantages from research and development are distributed fairly.
The question of pathogen access and benefit-sharing has been a long-standing point of tension between developed and developing nations. Countries in the Global South argue that they often bear the brunt of disease outbreaks yet receive limited returns when pharmaceutical companies develop diagnostics, treatments, and vaccines using biological materials sourced from their territories. Wealthier nations, meanwhile, have raised concerns about intellectual property protections and the speed at which research pipelines can be disrupted by lengthy regulatory frameworks.
Sources close to the negotiations indicate that several member states emphasized the need for a cooperative rather than adversarial approach. Diplomats stressed that the COVID-19 pandemic exposed critical gaps in the existing system, where uneven access to vaccines and therapeutics disproportionately affected low- and middle-income countries. The call for constructive engagement reflects a desire to move past years of deadlock and make tangible progress on what remains one of the most polarizing topics in multilateral health policy.
India, a key player in global vaccine manufacturing and a strong advocate for equitable access to medical countermeasures, has consistently supported frameworks that prioritize benefit-sharing for developing nations. Other members of the G77 and China bloc have echoed similar positions, arguing that any future agreement must include binding commitments on technology transfer, capacity building, and fair pricing of medical products derived from shared pathogen resources.
The discussion is expected to continue in upcoming WHO sessions, where delegates will work toward a consensus-based resolution that balances sovereignty concerns with the imperatives of global health security.
